 Drug Design
"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 2 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 3 | 3 | 6 | | 2006 | 1 | 4 | 5 | | 2007 | 2 | 4 | 6 | | 2008 | 3 | 7 | 10 | | 2009 | 0 | 6 | 6 | | 2010 | 5 | 3 | 8 | | 2011 | 4 | 5 | 9 | | 2012 | 5 | 6 | 11 | | 2013 | 2 | 7 | 9 | | 2014 | 1 | 2 | 3 | | 2015 | 3 | 1 | 4 | | 2016 | 3 | 3 | 6 | | 2017 | 1 | 5 | 6 | | 2018 | 1 | 3 | 4 | | 2019 | 0 | 5 | 5 | | 2020 | 2 | 1 | 3 | | 2021 | 2 | 3 | 5 | | 2022 | 0 | 2 | 2 | | 2023 | 1 | 0 | 1 | | 2024 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
Karolczak J, Przybylowska A, Szewczyk K, Taisner W, Heumann JM, Stowell MHB, Nowicki M, Brzezinski D. Ligand identification in CryoEM and X-ray maps using deep learning. Bioinformatics. 2024 12 26; 41(1).
-
Bricelj A, Dora Ng YL, Gobec M, Kuchta R, Hu W, Javornik ?, Ro?ic M, G?tschow M, Zheng G, Kr?nke J, Steinebach C, Sosic I. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. Chemistry. 2024 Aug 12; 30(45):e202400430.
-
Gardner L, Rossi J, Armstrong B, Muse M, LaVeck A, Blevins MA, Zhang L, Ford HL, Zhao R, Wang X. Rational Design of Novel Allosteric EYA2 Inhibitors as Potential Therapeutics for Multiple Brain Cancers. ChemMedChem. 2024 Sep 16; 19(18):e202400179.
-
Reusch JE. Building a Better Insulin - Whom Will It Help? N Engl J Med. 2023 Jul 27; 389(4):372-373.
-
El-Khouly OA, Henen MA, El-Sayed MA, El-Messery SM. Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer. Sci Rep. 2022 10 12; 12(1):17104.
-
Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
-
Buzzi RM, Owczarek CM, Akeret K, Tester A, Pereira N, Butcher R, Br?gger-Verdon V, Hardy MP, Illi M, Wassmer A, Vallelian F, Humar R, Hugelshofer M, Buehler PW, Gentinetta T, Schaer DJ. Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics. Mol Pharm. 2021 08 02; 18(8):3158-3170.
-
Sarkar A, Kim EY, Jang T, Hongdusit A, Kim H, Choi JM, Fox JM. Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products. ACS Synth Biol. 2021 06 18; 10(6):1505-1519.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
-
Eller KA, Aunins TR, Courtney CM, Campos JK, Otoupal PB, Erickson KE, Madinger NE, Chatterjee A. Facile accelerated specific therapeutic (FAST) platform develops antisense?therapies to counter multidrug-resistant bacteria. Commun Biol. 2021 03 12; 4(1):331.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|